MORE►
Sean Nolan
[Source image: istockphoto]
Taysha Gene Therapies Raises $150M for Its Rare Disease Drug Pipeline
by Lance Murray | Aug 16, 2023
Led by new investor RA Capital Management, the new funding is expected to extend Taysha's cash runway into the third quarter of 2025, and aid in its development of a gene therapy treatment targeting Rett Syndrome, a neurological disorder that occurs primarily in girls.
by Quincy Preston |
Dec 19, 2022
Dallas-based Taysha Gene Therapies is starting a new chapter in its fight to tackle devastating neurological conditions with changes in its top executive leadership.
Late Friday, the publicly traded biotech announced that Sean P....
MORE►
